Form 4: Anna French, Jasper Therapeutics Director, Granted Stock Options
SEC Form 4 Filing
Anna French, a director at Jasper Therapeutics, was granted stock options to purchase 7,500 shares of voting common stock on June 6, 2024.
Summary
- Anna French, a director of Jasper Therapeutics, Inc., filed a Form 4 on June 10, 2024, reporting a transaction.
- On June 6, 2024, she was granted stock options to purchase 7,500 shares of voting common stock at an exercise price of $25.41 per share.
- These options are exercisable beginning June 6, 2025, and expire on June 6, 2034.
- A Power of Attorney was executed on May 31, 2024, granting Ronald Martell and Herb Cross the authority to act on Anna French's behalf for SEC filings.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns director interests with shareholders. The sentiment is slightly positive due to the incentive provided by the stock options.
Positives
- The granting of stock options to a director aligns their interests with those of the shareholders.
- The vesting schedule (exercisable from June 6, 2025) encourages long-term commitment from the director.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's future performance.
Industry Context
Stock options are a common form of executive compensation in the biotechnology industry, used to incentivize performance and align management's interests with those of shareholders. This grant is a typical component of director compensation packages.
Comparison to Industry Standards
- Stock option grants are a standard practice for compensating directors in publicly traded companies, particularly in the biotech sector.
- The size of the grant (7,500 shares) and the exercise price ($25.41) would need to be compared to similar companies of Jasper Therapeutics' size and stage to determine if it is within industry norms.
- Companies like Sangamo Therapeutics or CRISPR Therapeutics could be considered peers for comparison of executive compensation practices.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes the director to work towards increasing shareholder value.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 2024-05-31 | Date of execution of the Power of Attorney. |
| 2024-06-06 | Date of the stock option grant. |
| 2024-06-06 | Date the stock options become exercisable. |
| 2024-06-10 | Date of Form 4 filing. |
| 2034-06-06 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.